Search Results for "Lipids"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Lipids. Results 51 to 60 of 144 total matches.

Vytorin: A Combination of Ezetimibe and Simvastatin

   
The Medical Letter on Drugs and Therapeutics • Sep 13, 2004  (Issue 1191)
cholesterol HMG-CoA reductase inhibitors statins Zocor Zetia simvastatin ezetimibe Vytorin cholesterol Lipid ...
Vytorin, a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe (Zetia - Merck/Schering Plough) and the HMG-CoA reductase inhibitor ("statin") simvastatin (Zocor - Merck), has been approved by the FDA for treatment of hypercholesterolemia. It is available as tablets containing 10 mg of ezetimibe combined with 10, 20, 40 or 80 mg of simvastatin.
Med Lett Drugs Ther. 2004 Sep 13;46(1191):73-4 |  Show IntroductionHide Introduction

Turmeric Supplements

   
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019  (Issue 1585)
. Effi cacy and safety of turmeric and curcumin in lowering blood lipid levels in patients ...
Turmeric is a spice derived from the Curcuma longa plant. Dietary supplements and foods containing turmeric are widely promoted for relief of pain and to improve joint mobility, immunity, digestion, cardiovascular health, depression, anxiety, memory, and cognition.
Med Lett Drugs Ther. 2019 Nov 18;61(1585):185 |  Show IntroductionHide Introduction

Voriconazole

   
The Medical Letter on Drugs and Therapeutics • Jul 22, 2002  (Issue 1135)
for invasive aspergillosis; it is also active against Fusarium spp. Three lipid formulations of amphotericin B ...
Voriconazole (Vfend -- Pfizer), an antifungal triazole structurally related to fluconazole (Diflucan) with a spectrum of action similar to that of itraconazole, has been approved by the FDA for primary treatment of invasive aspergillosis and for refractory infection with Scedosporium apiospermum (the asexual form of Pseudallescheria boydii) or Fusarium spp.
Med Lett Drugs Ther. 2002 Jul 22;44(1135):63-5 |  Show IntroductionHide Introduction

Drugs for Intermittent Claudication

   
The Medical Letter on Drugs and Therapeutics • Feb 16, 2004  (Issue 1176)
-CoA reductase inhibitors statins hypertension ACE inhibitors ramipril Altace Exercise Lipid-lowering ...
Management of intermittent claudication, the most common symptom of peripheral arterial disease (PAD), involves both risk factor modification and symptomatic treatment (WR Hiatt, N Engl J Med 2001; 344:1608; RM Schainfeld, J Am Board Fam Pract 2001; 14:443).
Med Lett Drugs Ther. 2004 Feb 16;46(1176):13-5 |  Show IntroductionHide Introduction

Pioglitazone/Glimepiride (Duetact) for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jan 29, 2007  (Issue 1253)
on serum lipids but whether the difference would result in more favorable cardiovascular outcomes ...
Duetact (Takeda), a new fixed-dose combination of the thiazolidinedione pioglitazone (Actos) and the sulfonylurea glimepiride (Amaryl, and others), was recently approved by the FDA for treatment of type 2 diabetes. It is approved as an adjunct to diet and exercise to improve glycemic control in patients already taking pioglitazone and/or a sulfonylurea. Avandaryl, a combination of glimepiride and the thiazolidinedione rosiglitazone, was approved in 2006.
Med Lett Drugs Ther. 2007 Jan 29;49(1253):9-11 |  Show IntroductionHide Introduction

Drug Interactions with Simvastatin

   
The Medical Letter on Drugs and Therapeutics • Oct 20, 2008  (Issue 1297)
appropriate studies are done. CONCLUSION — Simvastatin is a useful lipid-lowering drug that is available ...
A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin (Zocor, and others) and green tea. Since it became available generically, simvastatin has surpassed atorvastatin (Lipitor) as the best selling statin. As such, it is probably the most common cause of statin-induced myopathy, which is often a result of drug interactions.
Med Lett Drugs Ther. 2008 Oct 20;50(1297):83-4 |  Show IntroductionHide Introduction

Is Indapamide (Lozol) Safer Than A Thiazide?

   
The Medical Letter on Drugs and Therapeutics • Nov 17, 1989  (Issue 805)
). Adverse effects of thiazide diuretics on glucose and lipid metabolism have been implicated ...
Recent advertisements for indapamide (Lozol - Rorer), an oral antihypertensive/diuretic (Medical Letter, 26:17, 1984), claim that the drug, unlike thiazide diuretics, does not significantly increase serum cholesterol and has a minimal impact on potassium. Indapamide has no thiazide ring but, like chlorthalidone (Hygroton; and others) and hydrochlorothiazide (HydroDiuril; and others), it does have a sulfamoyl benzamide moiety, which is probably responsible for its natriuretic and diuretic effects. Unlike the thiazides, it also has a methylindoline moiety, which apparently decreases...
Med Lett Drugs Ther. 1989 Nov 17;31(805):103 |  Show IntroductionHide Introduction

Isradipine For Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 31, 1991  (Issue 845)
beta-blockers or high doses of diuretics, isradipine does not increase serum lipid concentrations ...
Isradipine (DynaCirc - Sandoz), a dihydropyridine calcium-channel blocker chemically related to nicardipine (Cardene) and nifedipine (Procardia, and others), was recently approved by the US Food and Drug Administration for oral treatment of hypertension.
Med Lett Drugs Ther. 1991 May 31;33(845):51-2 |  Show IntroductionHide Introduction

Dehydroepiandrosterone (DHEA)

   
The Medical Letter on Drugs and Therapeutics • Oct 11, 1996  (Issue 985)
, 1995). Whether DHEA has any effect on body composition, fat distribution, serum lipid levels ...
Dehydroepiandrosterone (DHEA) is an adrenal androgen now being marketed as a "food supplement"in health food stores. DHEA is not approved for any indication by the US Food and Drug Administration (FDA).
Med Lett Drugs Ther. 1996 Oct 11;38(985):91-2 |  Show IntroductionHide Introduction

In Brief: Rhabdomyolysis with Ezetimibe

   
The Medical Letter on Drugs and Therapeutics • Feb 28, 2005  (Issue 1203)
cholesterol lowering (Drugs for Lipids, Treat Guidel Med Lett 2005; 3:15). The advisory did not specify ...
Health Canada, the Canadian equivalent of the FDA, recently issued a public advisory about postmarketing reports of myalgia, rhabdomyolysis, hepatitis, pancreatitis and thrombocytopenia associated with use of ezetimibe (Zetia in the US; Ezetrol in Canada). Ezetimibe is often added to a statin to increase LDL cholesterol lowering (Drugs for Lipids, Treat Guidel Med Lett 2005; 3:15). The advisory did not specify whether these patients were also taking a statin, but according to the Canadian manufacturer Merck Frosst/Schering (Merck/Schering-Plough in the US), some of the patients who developed...
Med Lett Drugs Ther. 2005 Feb 28;47(1203):17 |  Show IntroductionHide Introduction